Activity‐Based Protein Profiling of Oxidases and Reductases

Krammer, Leo; Breinbauer, Rolf

doi:10.1002/ijch.202200086

Cited by 2 publications

(2 citation statements)

References 86 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…So far, very few oxidoreductases have been identified as antimalarial drug targets. [13,14] In the last decade, we have discovered an early lead redoxactive compound, called plasmodione (PD), belonging to the 3benzylmenadione (benzylMD) family, with a unique mechanism of action [15] that has been partly deciphered (Figure 1, panel A). PD acts as a prodrug entering in a cascade of redox reactions, with highest activity in young early stages and gametocytes.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Proteomic Profiling of Antimalarial Plasmodione Using 3‐Benz(o)ylmenadione Affinity‐Based Probes

Iacobucci,

Monaco,

Hovasse

et al. 2024

ChemBioChem

View full text Add to dashboard Cite

Understanding the mechanisms of drug action in malarial parasites is crucial for the development of new drugs to combat infection and to counteract drug resistance. Proteomics is a widely used approach to study host‐pathogen systems and to identify drug protein targets. Plasmodione is an antiplasmodial early‐lead drug exerting potent activities against young asexual and sexual blood stages in vitro with low toxicity to host cells. To elucidate its molecular mechanisms, an affinity‐based protein profiling (AfBPP) approach was applied to yeast and P. falciparum proteomes. New (pro‐)AfBPP probes based on the 3‐benz(o)yl‐6‐fluoro‐menadione scaffold were synthesized. With optimized conditions of both photoaffinity labeling and click reaction steps, the AfBPP protocol was then applied to a yeast proteome, yielding 11 putative drug‐protein targets. Among these, we found four proteins associated with oxidoreductase activities, the hypothesized type of targets for plasmodione and its metabolites, and other proteins associated with the mitochondria. In Plasmodium parasites, the MS analysis revealed 44 potential plasmodione targets that need to be validated in further studies. Finally, the localization of a 3‐benzyl‐6‐fluoromenadione AfBPP probe was studied in the subcellular structures of the parasite at the trophozoite stage.

show abstract

Section: Introductionmentioning

confidence: 99%

“…Open access to the full Plasmodium genome and proteome has brought new opportunities to identify novel drug targets. So far, very few oxidoreductases have been identified as antimalarial drug targets [13,14] …”

Section: Introductionmentioning

confidence: 99%